Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16961460 | 0.82 | HSD11B1 (0.34) | HSD11B1SCN9A | |
| SCHEMBL16952938 | 0.82 | KCNH2 (0.31) | — | |
| SCHEMBL17046411 | 0.78 | KDM4E (0.36) | GAA | |
| SCHEMBL1191364 | 0.76 | CA1 (0.41) | GAA | |
| SCHEMBL6735306 | 0.75 | KCNN4 (0.33) | GAA | |
| SCHEMBL4404035 | 0.73 | AR (0.36) | SLC22A12HSD11B1SCN9A | |
| SCHEMBL622920 | 0.73 | DDB1 (0.34) | GAAHSD11B1SCN9A | |
| SCHEMBL160453 | 0.73 | EPHX2 (0.35) | GAAHSD11B1SCN9A | |
| SCHEMBL4290698 | 0.72 | AR (0.38) | SLC22A12 | |
| SCHEMBL591521 | 0.72 | GRIA1 (0.36) | SLC22A12GAAHSD11B1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759390-B2 | chemokine receptor 9(CCR9) antagonists such as, 5-Chloro-thiophene-2-sulfonic acid (4-cyano-2-methyl-phenyl)-amide, used for treating autimmune and inflammatory diseases, transplantat rejection and cancer | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | claimed |
| US-20080300295-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-12-04 | — | — | US | claimed |
| EP-1966182-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071440-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| EP-2900645-B1 | HERBICIDAL AND FUNGICIDAL 3-PHENYLISOXAZOLIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| EP-3167716-A1 | SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2017-05-17 | — | — | EP | disclosed |
| US-9585392-B2 | 3-phenylisoxazolin derivatives with herbicidal action | BAYER CROPSCIENCE AG (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20150245615-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | BAYER CROPSCIENCE AG (DE) | 2015-09-03 | — | — | US | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-7759390-B2 | chemokine receptor 9(CCR9) antagonists such as, 5-Chloro-thiophene-2-sulfonic acid (4-cyano-2-methyl-phenyl)-amide, used for treating autimmune and inflammatory diseases, transplantat rejection and cancer | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| US-20080300295-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-12-04 | — | — | US | disclosed |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | disclosed |
| US-6683029-B1 | Halopyrimidines | BAYER AKTIENGESELLSCHAFT (DE) | 2004-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300295-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | SLC22A12 2846/4885GAA 3634/4885HSD11B1 960/4885 |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | SLC22A12 2675/4885GAA 1568/4885HSD11B1 585/4885 |
| US-20150245615-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | CYP4X1, CBR3, PAOX | SLC22A12 2211/4885GAA 1006/4885HSD11B1 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.